Companies: 10,795·Total market cap: $144.5T
Pardes Biosciences, Inc.

Pardes Biosciences, Inc.

PRDSNASDAQHealthcare
$2.18
+$0.02(+0.93%)
Market Cap$135185724
P/E Ratio—
52W High$3.67
52W Low$0.75
Overview

Pardes Biosciences, Inc.（PRDS）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

prds · 股价预测 · 3 位分析师（近3月）· FMP · 更新于 2024年10月11日

分析师评级与共识

基于过去 3 个月内 3 位华尔街分析师

SellBuy

Hold

3 位分析师

共识

评级分布

Strong Buy
0
Buy
1
Hold
2
Sell
0
Strong Sell
0
合计: 3 · 买入占比: 33.3%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $2.16

Pardes Biosciences, Inc.（PRDS）的分析师共识为 Hold，基于过去 3 个月内 3 位华尔街分析师的评级。PRDS 的 12 个月平均目标价为 $0.00，相对当前价 $2.16 代表 +0.0% 的潜在上行空间。

短期股价预测

⚠️ 短期模型暂不可用——近期成交量过低，信号不可靠。

长期股价预测

⚠️ 长期模型暂不可用——成交量过低，信号不可靠。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BULLISH

Based on 14 technical indicators

79%7%14%
11Buy
1Neutral
2Sell
RSI (14)100.0Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · PRDS · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$2.16NEUTRAL
MA 10$2.16BUY
MA 20$2.14BUY
MA 50$2.07BUY
MA 100$1.97BUY
MA 200$1.74BUY
Current $PRDS · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.16BUY
EMA 10$2.15BUY
EMA 20$2.14BUY
EMA 50$2.07BUY
EMA 100$1.98BUY
EMA 200$2.22SELL
Current $PRDS · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
JMP Securities2023-07-18
Downgrade ↓
Market Outperform→Market Perform
JMP Securities2023-07-17
Downgrade ↓
Market Outperform→Market Perform
SVB Leerink2023-04-04
Downgrade ↓
Outperform→Market Perform
SVB Leerink2023-04-03
Downgrade ↓
Outperform→Market Perform
JMP Securities2023-03-15
Maintains
Market Outperform→Market Outperform
JMP Securities2023-03-14
Maintains
Market Outperform→Market Outperform
SVB Leerink2023-01-27
Maintains
Outperform→Outperform
SVB Leerink2023-01-26
Maintains
Outperform→Outperform
JMP Securities2022-12-13
Maintains
Market Outperform→Outperform
SVB Leerink2022-08-16
Maintains
Outperform→Outperform

Wall Street analysts have recently issued updated ratings on Pardes Biosciences, Inc. (PRDS) stock. Of the recent 13 rating actions, 0 were upgrades and 4 were downgrades. 3 analysts currently cover PRDS.

分析师推荐趋势

Buy ratings2 → 0↓ 2
Hold ratings0 → 2↑ +2
Sell ratings0 → 0

PRDS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

—

Revenue Next Year

—

EPS This Year

—

EPS Next Year

—

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PRDS EPS of $— for the current fiscal year, based on estimates from 0 analysts. The PRDS revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

PRDS 股价预测由两类独立数据源支撑：来自 3 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PRDS 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Hold。

Pardes Biosciences, Inc. 在 NASDAQ 上市，代码 PRDS。PRDS 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 33% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

PRDS 预测 · 8 个问题

根据 3 位华尔街分析师，PRDS 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $2.16，隐含约 +0.0% 的上行空间。

PRDS 目标价PRDS 分析师目标价PRDS 12个月目标价目标价 PRDS

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.